COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in… Dec 13, 2021
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360… Dec 1, 2021
First-ever Human Data on SSRI – Psilocybin Interactive Effects Published by MindMed and Liechti Lab Nov 30, 2021